Physician profile
Christina Clay
NPI 1326029042
$5,508.18
in general payments reported to CMS, 2019-2025
31 companies · $37.38 in 2025
The $37.38 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,960 · 2022: $207 · 2023: $57.47 · 2024: $3,246 · 2025: $37.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,125 · Food and Beverage: $198 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,125.00 |
| Food and Beverage | $198.20 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,249.90 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $352.75 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $256.19 | 2019-2024 | |
| Genentech USA, INC. | $249.92 | 2019 | |
| Novocure INC. | $195.19 | 2022 | |
| Janssen Biotech, INC. | $182.18 | 2019 | |
| Eisai INC. | $171.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $146.41 | 2019 | |
| Merck Sharp & Dohme LLC | $91.04 | 2019-2024 | Welireg |
| Celgene Corporation | $89.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $62.61 | 2019 | |
| Lilly USA, LLC | $52.45 | 2019 | |
| Abbvie INC. | $44.67 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $41.14 | 2019 | |
| Amgen INC. | $30.81 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.71 | 2019 | |
| Foundation Medicine, INC. | $26.24 | 2019 | |
| Genzyme Corporation | $24.99 | 2019 | |
| Exelixis INC. | $21.10 | 2019 | |
| Gt Medical Technologies, INC | $21.07 | 2025 | Gammatile |
| Aurobindo Pharma USA, INC. | $20.76 | 2019 | |
| Seagen INC. | $18.15 | 2019 | |
| Gilead Sciences, INC. | $16.46 | 2019 | |
| Geron Corporation | $16.31 | 2025 | Rytelo |
| Tesaro, INC. | $15.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.27 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.59 | 2019 | |
| Puma Biotechnology, INC. | $13.89 | 2023 | |
| Taiho Oncology, INC. | $13.63 | 2019 | |
| Global Blood Therapeutics, INC. | $12.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.